Respiratory syncytial virus clinical trial


If you are between 18 and 49 years of age and are 24 to 33 weeks pregnant.

Trial status:


Respiratory syncytial virus, or RSV, is a common respiratory (lungs and airways) virus that usually causes mild, cold-like symptoms. Often people recover in a week or two, but RSV can be deadly, especially for infants and older adults.

Currently, there is no specific treatment or approved vaccine to protect our infant population against RSV. Mater is running a RSV vaccine study in pregnant women at Mater Mothers' Hospital and we need your help.

If you are between 18 and 49 years of age and are 24 to 33 weeks pregnant and are interested in being part of this important study, please contact our team for more information.

All research clinical trials news

Mater Researchers have launched a trial to discover if laser light therapy can relieve some of the debilitating symptoms of IBD in young people.



Mater Research leads world-first laser light therapy trial for bowel disease

This International Clinical Trials Day, Friday 20 May 2022, Mater is shining a light on the more than 200 clinical trials being run through Mater Research and Mater Hospitals that aim to improve...



Trialling discoveries to deliver better treatments

Mater Research is calling for 50 adults in south-east Queensland to join the global clinical trial of a potential new protein-based COVID-19 vaccine, the latest vaccine trial being run at Mater...



Volunteers needed for new COVID-19 vaccine trial

Displaying results 1-3 (of 8)
 |<  < 1 - 2 - 3  >  >|